Medline Inc. (NASDAQ: MDLN) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $34.4B. The Maz Rating grades it against the other companies in its sector.
Medline Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $39.17, Medline Inc. trades at 58.5x trailing earnings, 1.1x sales and 2.9x book value, with an EV/EBITDA of 17.1. Over the last twelve months it generated about $30.7B of revenue and $589M of net income. It runs a gross margin of 25.2%, an operating margin of 5.7% and a net margin of 1.8%. It shows return on equity of 5.0%, return on invested capital of 3.7% and a free cash flow yield of 5.5%. On the balance sheet: a debt-to-equity ratio of 1.07 and a current ratio of 4.04. Over the past 52 weeks the share price ranged from $31.37 to $50.88, with a beta of -0.39.
Medline Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 17 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Medline Inc. (MDLN) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 40.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.7% / 30% · Interest income / Revenue 0.60% / 5% | Fail |
| S&P Global |
|---|
| Debt / Mkt Cap (36m) 40.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.7% / 33% · Receivables / Mkt Cap (36m) 12.3% / 49% · Interest income / Revenue 0.60% / 5% |
| Fail |
| Dow Jones | Debt / Mkt Cap (24m) 40.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.7% / 33.33% · Receivables / Mkt Cap (24m) 12.3% / 33.33% · Interest income / Revenue 0.60% / 5% | Fail |
|---|
| MSCI | Debt / Avg Assets (4Q) 32.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.66% / 33.33% · Receivables / Avg Assets (4Q) 9.34% / 33.33% · Interest income / Revenue 0.60% / 5% | Pass |
|---|
| FTSE | Debt / Total Assets 31.3% / 33.33% · (Cash+ST Inv) / Total Assets 8.98% / 33.33% · (Cash+Recv) / Total Assets 18.4% / 33.33% · Interest income / Revenue 0.60% / 5% | Pass |
|---|
It depends on the standard you follow. As of September 2026, Medline Inc. (MDLN) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Medline Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.60% of each dividend: Medline Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 26, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.